Advancements in biotechnology have made the large-scale development of biological drugs easier and more cost-effective to develop. While chemical-based drugs remain most prevalent, the total share of biologic drugs has increased significantly in recent years, representing more than 25% of the pharmaceutical market and more growth is expected with annual revenue to reach US$ 727 billion by 2025.
What does this growing trend mean for the industry at large? Download this whitepaper to learn more about:
- The analysis of global patent activity as a predictor for biologics growth
- Leading technology areas in biosequence patents
- Acquiring Innovation: building versus buying
- Top organizations leading biotechnology and biopharma innovation
- Biotechnology hot spots around the globe
